Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Outlining Exercise as a “Biologically Interventional Therapy” for Cancer
3
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
4
FDA Approves Dato-DXd for Metastatic Triple-Negative Breast Cancer
5